Prognostic impact of neoadjuvant chemotherapy in patients with synchronous colorectal liver metastasis: A propensity score matching comparative study

• DOI: 10.1016/j.ijsu.2021.106106
• Publication Date: 2021-09-15T16:01:27Z
• Authors: Masaki Ueno; Koji Komeda; Hisashi Kosaka; Takuya Nakai; Takeo Nomi; Hiroya Iida; Shogo Tanaka; Hisashi Ikoma; Kenji Matsuda; Fumitoshi Hirokawa; Masataka Matsumoto; Daisuke Hokuto; Haruki Mori; Ryo Morimura; Masaki Kaibori; Hiroki Yamaue; Shoji Kubo
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Chemotherapy, Adjuvant; Liver Neoplasms; Hepatectomy; Humans; Colorectal Neoplasms; Prognosis; Propensity Score; Neoadjuvant Therapy; Retrospective Studies; 3. Good health

Synchronous colorectal liver metastasis (SCRLM) is at an advanced tumor stage and requires multidisciplinary treatments. Neoadjuvant chemotherapy (NAC) is thought to be an effective treatment modality, but its prognostic impact is still unclear.Patients with resectable SCRLM presented to eight university hospitals between 2007 and 2017 were retrospectively reviewed. Propensity score matching (PSM) was performed to adjust baseline characteristics between patients who received NAC with those who underwent up-front hepatectomy. The prognostic impact of NAC was then evaluated.The cohort comprised of 320 patients: 151 patients received NAC and the remaining 169 patients underwent up-front hepatectomy. After a 1:1 ratio of PSM, 102 patients per group were selected. Within the PSM cohort, 66% patients had multiple liver tumors, with 15% having five or more liver tumors. The median survival (95% confidence interval) periods for patients with and without NAC in the PSM cohort were 88.5 (68.4 - not reached) and 84.2 (52.1 - not reached) months, respectively (P = 0.51). On multivariate analysis, the postoperative events in these patients including operative complications and use of adjuvant chemotherapy after hepatectomy were prognostic factors with hazards (95% confidence interval) being 1.88 (1.18-2.98) and 0.65 (0.42-1.01), respectively.This PSM study was restricted to patients with SCRLM and relatively advanced tumor stagings. NAC did not show any significant prognostic impact. While operative complications had a significant prognostic impact, use of adjuvant chemotherapy after hepatectomy had only a marginal prognostic impact. Reconsideration of indications for NAC is needed.